The Foundation’s commitment to these principles will continue to be a cornerstone of the Foundation’s work to advance our mission in 2023.
The Cystic Fibrosis Foundation’s investment will go toward conducting preclinical research on a novel gene delivery vehicle. If successful, this gene delivery method could overcome some of the biggest challenges to delivering a gene therapy into the lung cells of people with cystic fibrosis.
206 care center directors sign a letter citing clinical consequences if decision moves forward.
The physical footprint of the Cystic Fibrosis Foundation Therapeutics Lab grew by about a third this year, enabling startup companies and industry scientists to work and learn alongside lab staff.
The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.
Vertex’s copay assistance changes add an undue burden for people living with an already expensive, challenging lifelong disease.
Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.
Results show that people on Trikafta® enrolled in the six-week study were able to safely stop taking one of the two common CF medications without negatively affecting their health.
The Cystic Fibrosis Foundation is providing up to $5 million to develop a method to deliver a healthy copy of the CFTR gene into the lung cells of people with CF that is unlikely to trigger an immune system response.
Addressing variability in newborn screening can prevent missed diagnoses and delays in early care intervention.